CJC-1295 (no DAC) + Ipamorelin — the stack

Published · Researched 2026-09-21

Research date: 2026-09-20

This is a combo entry: the stack is treated as its own community entity because that is how it is bought, dosed, and discussed — as a paired protocol, not as two separate products.

Overview

The CJC-1295 (no DAC) + Ipamorelin stack pairs two distinct research chemicals used together to produce pulsatile growth-hormone release through two receptors at once:

  • CJC-1295 without DAC — a GHRH (growth hormone–releasing hormone) analog that binds the GHRH receptor on pituitary somatotrophs, extending the GH synthesis signal. "No DAC" means no Drug Affinity Complex, so it is short-acting (Mod GRF 1-29 is the related/synonymous name in community usage).
  • Ipamorelin — a selective ghrelin-receptor (GHS-R1a) agonist that triggers GH exocytosis via a separate calcium-surge pathway, with minimal effect on cortisol or prolactin.

Neither compound is a product, approved, or sold together by any pharmaceutical company — the "stack" is a community protocol pattern, and pre-mixed blend vials exist only in the grey market.

Social standing

Platform pulse: the dominant GH stack across all four platforms. It is the most-recurring combination in the 170-post social dataset, dominating Instagram educational reels, Facebook groups, and FB page promos.

  • Instagram: RIPD.FIT's January 2026 graphic "MAXIMUM MUSCLE GAIN PEPTIDE STACK" lists CJC-1295 NO DAC (100 mcg) 3× daily alongside Ipamorelin (100 mcg) 3× daily — the clearest published community protocol anchor. HNR Labs' educational motion graphic explains the synergy as "two signals combine into one bigger pulse." Dr. Pat Taylor (Chief Medical Officer, Live Vital/Belle Health) ran a clinical-promotional carousel calling it "THE MOST POPULAR STACK YOU HAVEN'T HEARD OF." GenDarwin Research published a 10-slide educational brief: "TWO PEPTIDES. TWO RECEPTORS. ONE AMPLIFIED RESULT." Coach Chris Lane (Coffee & Peppers) explained it with a football analogy ("CJC calls the play, Ipamorelin triggers the snap"), stressing it is not HGH but upstream signaling. Wise Longevity and @chemicalupgrade ran week-by-week effect timelines. A viral Homelander meme documents the "cjc flush" — the panicked first-dose flushing reaction.
  • FB Groups: Threads show enthusiastic self-reporting — improved sleep quality, harder-feeling muscles, faster recovery within weeks (June 2026 group thread). One woman's thread documented dose critiques: her stated 500 mcg was flagged as excessive against the typical 100–300 mcg range. Dosing protocols shared include 3 months on / 1 month off and fasted nighttime administration.
  • FB Pages / clinicians: A Miami clinic reel (Holistic Health and Medical) sells both vials with COA alongside transformation claims. Dr. Jason Pencek's infographic series contrasts the stack against HGH somatropin and tesamorelin, arguing "stronger is not always smarter." Dr. Nessim (MD) posted citing human trials with acceptable safety, noting expected water retention and transient injection-site reactions.
  • Threads: Discussion is thinner but present in biohacking accounts cross-posting the same educational content.

Group consensus: Broadly enthusiastic; self-reports of better sleep and recovery dominate, with technical nuance widely known — e.g., commenters correcting timeline posts to note that only Ipamorelin (not CJC) needs cycling off due to ghrelin-receptor desensitization.

Main praise: improved sleep quality, faster recovery, perceived muscle fullness and fat loss, lower cost than tesamorelin or HGH, and a more "physiologic" pathway than direct GH.

Main complaints: the "CJC flush" (flushing, sometimes nausea) on first doses; sleep disruption in some users; water retention, headaches, pins-and-needles; injection burden (1–3× daily); heavy supplier spam in comments ("DM for price lists", Napsgear/PepSource copy-paste replies, Telegram vendor links) — a strong hype/spam signal.

Short attributed quotes: HNR Labs: "two signals combine into one bigger pulse" (synergy pitch); RIPD.FIT graphic: "MAXIMUM MUSCLE GAIN PEPTIDE STACK"; Dr. Pat Taylor: "THE MOST POPULAR STACK YOU HAVEN'T HEARD OF".

Social validation

Tier 1 — the single most-discussed GH peptide combination in the social dataset.

Source What it proves
https://www.instagram.com/reel/DTfixxSE62G/ (RIPD.FIT, Jan 2026) The canonical community protocol: CJC-1295 NO DAC + Ipamorelin at 100 mcg 3× daily
https://www.facebook.com/reel/1916825249295818/ (HNR Labs) Educational framing of the synergy; comments full of user self-reports (sleep, water retention, flushing) and supplier spam
https://www.instagram.com/p/DdASh58vlzi/ (Dr. Pat Taylor, Sep 2026) Clinical-promotional validation of the stack as the mainstream choice over tesamorelin
https://www.instagram.com/reel/DZqF3egPsdJ/ (Bryan Johnson, Jun 2026) A cautionary counter-example: he abandoned CJC-1295 DAC (not this stack) after 2 doses over biomarker worsening — the community heavily debates DAC vs no-DAC
https://www.facebook.com/groups/1927446947964069/permalink/1996173291091434/ (Sep 2026) Real group debate on dosing schedules (3 on/1 off) and cost comparisons

Key specs table

Spec Value
Class GHRH analog (CJC-1295 no DAC) + selective ghrelin-receptor agonist (Ipamorelin)
Mechanism Dual-receptor stimulation of pituitary somatotrophs: cAMP-mediated GH synthesis (GHRH receptor) + calcium-mediated GH exocytosis (GHS-R1a) → amplified GH pulse
Half-life CJC-1295 no DAC: short (minutes–hours class range, UNVERIFIED precisely); Ipamorelin: ~2 h class range (UNVERIFIED precisely) — the stack is short-acting and pulsatile by design, unlike the DAC variant
Route Subcutaneous injection (both)
Community-reported dosing 100 mcg of each, 1–3× daily; the most-cited pattern is 100 mcg 3× daily (RIPD.FIT graphic, Jan 2026); 100–300 mcg range common in groups; 5 days on / 2 days off and 3 months on / 1 month off patterns reported; nighttime fasted dosing preferred. Reported as community patterns, not instructions.
MW / CAS UNVERIFIED for this entry (two separate compounds)

Pricing

  • No combined-product pricing verified. The stack is run as two separate vials; cost = cost of both. Grey-market vial sizes commonly seen: 5 mg and 10 mg blend or separate vials (per vendor product imagery, 2026).
  • Research-chem per-vial prices: UNVERIFIED — not price-checked in this batch; prices vary by vendor and are frequently listed in group comments rather than on pages.
  • Clinics (e.g., the Miami clinic reel) bundle both vials with COA — clinic prices: UNVERIFIED.
  • Marketplace: no listings observed 2026-09-20 (FB Marketplace returned zero results for peptide queries).

What's included / what's needed

Factual contents: grey-market offerings are lyophilized powder vials of each peptide (separate or pre-blended), sometimes bundled with bacteriostatic water and syringes. Pharma kits do not exist — there is no manufacturer packaging for this combination. (No use instructions are provided here.)

Support reality

Research-chem COA culture — vendor-provided Certificates of Analysis are the only quality signal, with heavy supplier spam in comments indicating a noisy market. A clinic channel exists alongside: longevity/HRT clinics (Miami example) sell both vials with COA and medical framing. No pharmaceutical company supports this combination; no patient-assistance or brand program applies.

Regulatory & safety status

  • Regulatory: Not a product — two unapproved research chemicals used together. Neither CJC-1295 nor Ipamorelin is FDA/EMA-approved for any indication.
  • WADA: Both prohibited — CJC-1295 under S2.2.4 (GHRH analogs) and Ipamorelin under S2.2.4 (GH secretagogues and their mimetics). Verified via https://www.drugs.com/wada/s2-peptide-hormones-growth-factors-and-related-substances.html (2026-09-20).
  • Safety signals (community-reported, from dataset): flushing ("CJC flush"), sleep disruption, water retention, headaches, pins-and-needles, transient injection-site reactions. A creator-run comparison of CJC vs tesamorelin noted water retention and joint-pain concerns when stacking GHRH analogs together. Long-term safety data: none published for this combination.

Community verdict

The CJC-1295/Ipamorelin stack is the default GH protocol of the 2026 peptide scene — endorsed from clinical-promotional carousels to FB group threads — because it delivers the most-cited sleep and recovery improvements at a fraction of HGH's cost, through a dual-receptor mechanism the community understands well. The trade is injection burden, flushing, and a grey-market supply chain saturated with vendor spam, with no long-term safety data behind the enthusiasm.

Image log

Open questions / UNVERIFIED

  • Per-vial research-chem prices — unverifiable without vendor price checks; not stated.
  • Clinic bundle pricing — unverifiable; not published on pages reviewed.
  • Precise half-lives of both compounds in the no-DAC form — unverifiable from sources reviewed.
  • Whether pre-blended vials dose accurately vs separate vials — unverifiable; community opinion only.
  • Long-term pituitary/desensitization outcomes of chronic use — no published data; unverifiable.

Not medical advice. This file is research documentation only; nothing here is a recommendation to use any compound.

CJC-1295 (no DAC) + Ipamorelin — the stack — box view
box view Original vendor page URL not recorded in research dossier
CJC-1295 (no DAC) + Ipamorelin — the stack — detail view
detail view Original vendor page URL not recorded in research dossier
CJC-1295 (no DAC) + Ipamorelin — the stack — hero view
hero view Original vendor page URL not recorded in research dossier
CJC-1295 (no DAC) + Ipamorelin — the stack — rear view
rear view Original vendor page URL not recorded in research dossier
CJC-1295 (no DAC) + Ipamorelin — the stack — side view
side view Original vendor page URL not recorded in research dossier

Sources